Endocrine Abstracts

Introduction: Immune check-point inhibitors (ICI) can cause adverse events in many organs due to the activation of T-cells. Data on the effect of ICI on bones and incidence of fracture is still scarce.Aim: To quantify the rate of osteoporotic fracture before and after the use of ICI in cancer patients.Methods: We retrospectively retrieved pertinent data of all patients who were treated with ICI between 2015 and 2023 at the Tel-Aviv...

Introduction: Severe insulinopenic diabetes (SID) is a rare complication of treatment with immune checkpoint inhibitors (ICPI). We describe herein the clinical characteristics, natural history and potential predictors of SID in cancer patients treated with ICPI.Methods: We identified and retrospectively retrieved pertinent clinical data of all patients who presented with new onset SID following treatment with ICPI between 2015 and 2022 at the Tel Aviv-So...